Eli Lilly’s Retatrutide Phase 3 Data Shocks the Market: Behind the 30% Weight Loss, the Peptide API Supply Chain Emerges as a New Hotspot

Eli Lilly’s Retatrutide Phase 3 data is reshaping the obesity drug market while accelerating global demand for peptide API manufacturing and supply chain capacity.

Top Stories

A New Direction in the Treatment of RAS-Mutant Cancers: Insights from Clinical Studies of daraxonrasib

How AI Reshapes Drug R&D: A Full-Chain Innovation from Target Discovery to Clinical Trials

Latest Coverage

A Breakthrough in Nebulized Antiviral Therapy: Phase III Progress of Peramivir Inhalation Solution
In the field of influenza treatment, traditional therapies have long relied on oral and intravenous administration ro...

Next-Generation MS Therapy Competition: BTK Inhibitors Are Reshaping the Landscape

How Pharmaceutical Distributors Respond to Transportation Requirements for Different Dosage Forms
As the global pharmaceutical supply chain continues to evolve, pharmaceutical transportation is no longer just about ...

Finerenone Approved for a New Indication in China: 18% Reduction in Heart Failure Events and New Progress in HFpEF Treatment
On May 21, 2026, German pharmaceutical company Bayer announced that its innovative drug Finerenone (Kerendia) has bee...

From Laboratory to Clinical Practice: The Translational Medicine Journey of Nanomedicine in Targeted Cancer Therapy
Nanomedicine is reshaping targeted cancer therapy through advanced drug delivery systems, precision-controlled treatm...

April 2026 Breakthroughs in Cancer Treatment: 26 New Projects Launched, Advances in Immunotherapy and Precision Targeting
Global oncology developments in April 2026 included 26 newly funded cancer research projects, advances in immunothera...

In-Depth Analysis

Eli Lilly’s Retatrutide Phase 3 Data Shocks the Market: Behind the 30% Weight Loss, the Peptide API Supply Chain Emerges as a New Hotspot

A New Direction in the Treatment of RAS-Mutant Cancers: Insights from Clinical Studies of daraxonrasib

How AI Reshapes Drug R&D: A Full-Chain Innovation from Target Discovery to Clinical Trials

A Breakthrough in Nebulized Antiviral Therapy: Phase III Progress of Peramivir Inhalation Solution